{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:34:13Z","timestamp":1766788453100,"version":"3.32.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of JiangXi Province of China","award":["20202BABL206096","20202BABL206096","20202BABL206096","20202BABL206096","20202BABL206096"],"award-info":[{"award-number":["20202BABL206096","20202BABL206096","20202BABL206096","20202BABL206096","20202BABL206096"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01650-5","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T13:20:13Z","timestamp":1735564813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CYFIP2: potential pancreatic cancer biomarker and immunotherapeutic target"],"prefix":"10.1007","volume":"15","author":[{"given":"Cong","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobo","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"1","key":"1650_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1650_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40880-019-0368-6","volume":"39","author":"RM Feng","year":"2019","unstructured":"Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 global cancer statistics\u201d Cancer Commun (Lond). 2019;39(1):22. https:\/\/doi.org\/10.1186\/s40880-019-0368-6.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"1650_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin"},{"issue":"7725","key":"1650_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","volume":"562","author":"H Ledford","year":"2018","unstructured":"Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize. Nature. 2018;562(7725):20\u20131. https:\/\/doi.org\/10.1038\/d41586-018-06751-0.","journal-title":"Nature"},{"key":"1650_CR5","doi-asserted-by":"publisher","first-page":"102283","DOI":"10.1016\/j.coi.2023.102283","volume":"80","author":"KP Burke","year":"2023","unstructured":"Burke KP, Patterson DG, Liang D, Sharpe AH. Immune checkpoint receptors in autoimmunity. Curr Opin Immunol. 2023;80:102283. https:\/\/doi.org\/10.1016\/j.coi.2023.102283.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"1650_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3892\/mmr.2021.12457","volume":"24","author":"Y Li","year":"2021","unstructured":"Li Y, Song X, Liu L, Yue L. NUAK2 silencing inhibits the proliferation, migration and epithelial-to-mesenchymal transition of cervical cancer cells via upregulating CYFIP2. Mol Med Rep. 2021;24(5):817. https:\/\/doi.org\/10.3892\/mmr.2021.12457.","journal-title":"Mol Med Rep"},{"issue":"14","key":"1650_CR7","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.2147\/IJGM.S335713","volume":"11","author":"J Tong","year":"2021","unstructured":"Tong J, Meng X, Lv Q, Yuan H, Li W, Xiao W, Zhang X. The downregulation of prognosis- and immune infiltration-related gene CYFIP2 serves as a novel target in ccRCC. Int J Gen Med. 2021;11(14):6587\u201399. https:\/\/doi.org\/10.2147\/IJGM.S335713.","journal-title":"Int J Gen Med"},{"issue":"4","key":"1650_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3892\/ol.2017.5743","volume":"13","author":"S Jiao","year":"2017","unstructured":"Jiao S, Li N, Cai S, Guo H, Wen Y. Inhibition of CYFIP2 promotes gastric cancer cell proliferation and chemoresistance to 5-fluorouracil through activation of the Akt signaling pathway. Oncol Lett. 2017;13(4):2133\u201340. https:\/\/doi.org\/10.3892\/ol.2017.5743.","journal-title":"Oncol Lett"},{"issue":"3","key":"1650_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/epi-2017-0118","volume":"10","author":"V Modhukur","year":"2018","unstructured":"Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277\u201388. https:\/\/doi.org\/10.2217\/epi-2017-0118.","journal-title":"Epigenomics"},{"issue":"D1","key":"1650_CR10","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, Shi X, Wang B, Li Z, Ren P, Sun L, Yan Y, Zhang P, Zhang F, Li T, Wang C. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucl Acid Res. 2021;49(D1):D1420\u201330. https:\/\/doi.org\/10.1093\/nar\/gkaa1020.","journal-title":"Nucl Acid Res"},{"issue":"1","key":"1650_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s40001-023-01366-2","volume":"28","author":"Q Peng","year":"2023","unstructured":"Peng Q, Ren B, Xin K, Liu W, Alam MS, Yang Y, Gu X, Zhu Y, Tian Y. CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers. Eur J Med Res. 2023;28(1):364. https:\/\/doi.org\/10.1186\/s40001-023-01366-2.","journal-title":"Eur J Med Res"},{"issue":"13","key":"1650_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954848","volume":"11","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, He S, Yu X, Lai X, Tang S, Mariya MEA, Wang M, Yan H, Huang X, Zeng S, Zha D. Analysis and experimental validation of rheumatoid arthritis innate immunity gene CYFIP2 and pan-cancer. Front Immunol. 2022;11(13): 954848. https:\/\/doi.org\/10.3389\/fimmu.2022.954848.","journal-title":"Front Immunol"},{"issue":"88","key":"1650_CR13","first-page":"2016","volume":"55","author":"L Badea","year":"2008","unstructured":"Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumour epithelia. Hepatogastroenterology. 2008;55(88):2016\u201327.","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"1650_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. Cluster profiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"issue":"269","key":"1650_CR15","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"},{"issue":"2","key":"1650_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees MG, Seashore-Ludlow B, Cheah JH, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12(2):109\u201316. https:\/\/doi.org\/10.1038\/nchembio.1986.","journal-title":"Nat Chem Biol"},{"key":"1650_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucl Acid Res. 2013. https:\/\/doi.org\/10.1093\/nar\/gks1111.","journal-title":"Nucl Acid Res"},{"issue":"4","key":"1650_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.devcel.2019.09.018","volume":"51","author":"A Juin","year":"2019","unstructured":"Juin A, Spence HJ, Martin KJ, et al. N-WASP control of LPAR1 trafficking establishes response to self-generated LPA gradients to promote pancreatic cancer cell metastasis. Dev Cell. 2019;51(4):431-445. e7. https:\/\/doi.org\/10.1016\/j.devcel.2019.09.018.","journal-title":"Dev Cell"},{"issue":"7","key":"1650_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/BCTT.S59006","volume":"24","author":"B Frugtniet","year":"2015","unstructured":"Frugtniet B, Jiang WG, Martin TA. Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis. Breast Cancer (Dove Med Press). 2015;24(7):99\u2013109. https:\/\/doi.org\/10.2147\/BCTT.S59006.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"1650_CR20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41556-018-0174-4","volume":"20","author":"J Liu","year":"2018","unstructured":"Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, Cao J, Zhang Z, Liu J, Lengyel E, He C. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20(9):1074\u201383. https:\/\/doi.org\/10.1038\/s41556-018-0174-4.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1650_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, Wei JF, Yang H. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18(1):110. https:\/\/doi.org\/10.1186\/s12943-019-1036-9.","journal-title":"Mol Cancer"},{"issue":"2","key":"1650_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/biom11020296","volume":"11","author":"V Nobile","year":"2021","unstructured":"Nobile V, Pucci C, Chiurazzi P, Neri G, Tabolacci E. DNA methylation, mechanisms of FMR1 inactivation and therapeutic perspectives for fragile X syndrome. Biomolecules. 2021;11(2):296. https:\/\/doi.org\/10.3390\/biom11020296.","journal-title":"Biomolecules"},{"issue":"2","key":"1650_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/biom11020296","volume":"11","author":"V Nobile","year":"2021","unstructured":"Nobile V, Pucci C, Chiurazzi P, Neri G, Tabolacci E. DNA methylation, mechanisms of FMR1 inactivation and therapeutic perspectives for fragile X syndrome. Biomolecules. 2021;11(2):296. https:\/\/doi.org\/10.3390\/biom11020296.","journal-title":"Biomolecules"},{"issue":"3","key":"1650_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s12276-023-00944-y","volume":"55","author":"Z Liu","year":"2023","unstructured":"Liu Z, Gao L, Cheng L, Lv G, Sun B, Wang G, Tang Q. The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications. Exp Mol Med. 2023;55(3):487\u2013501. https:\/\/doi.org\/10.1038\/s12276-023-00944-y.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1650_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. https:\/\/doi.org\/10.1186\/s12943-019-1109-9.","journal-title":"Mol Cancer"},{"issue":"1","key":"1650_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-020-01204-7","volume":"19","author":"T Wang","year":"2020","unstructured":"Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in cancer progression. Mol Cancer. 2020;19(1):88. https:\/\/doi.org\/10.1186\/s12943-020-01204-7.","journal-title":"Mol Cancer"},{"issue":"4","key":"1650_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168(4):629\u201343. https:\/\/doi.org\/10.1016\/j.cell.2016.12.013.","journal-title":"Cell"},{"issue":"5","key":"1650_CR28","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3892\/ijo.2017.3919","volume":"50","author":"YS Chang","year":"2017","unstructured":"Chang YS, Huang HD, Yeh KT, Chang JG. Identification of novel mutations in endometrial cancer patients by whole-exome sequencing. Int J Oncol. 2017;50(5):1778\u201384. https:\/\/doi.org\/10.3892\/ijo.2017.3919.","journal-title":"Int J Oncol"},{"issue":"1","key":"1650_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-18-0120","volume":"26","author":"T Vandamme","year":"2019","unstructured":"Vandamme T, Beyens M, Boons G, Schepers A, Kamp K, Biermann K, Pauwels P, De Herder WW, Hofland LJ, Peeters M, Van Camp G, Op de Beeck K. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2019;26(1):1\u201312. https:\/\/doi.org\/10.1530\/ERC-18-0120.","journal-title":"Endocr Relat Cancer"},{"key":"1650_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102070","volume":"89","author":"D Uprety","year":"2020","unstructured":"Uprety D, Adjei AA. KRAS: from undruggable to a druggable cancer target. Cancer Treat Rev. 2020;89: 102070. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102070.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1650_CR31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Sign Transduct Target Ther. 2021;6(1):386. https:\/\/doi.org\/10.1038\/s41392-021-00780-4.","journal-title":"Sign Transduct Target Ther"},{"issue":"16","key":"1650_CR32","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1093\/emboj\/18.16.4424","volume":"18","author":"E Saller","year":"1999","unstructured":"Saller E, Tom E, Brunori M, Otter M, Estreicher A, Mack DH, Iggo R. Increased apoptosis induction by 121F mutant p53. EMBO J. 1999;18(16):4424\u201337. https:\/\/doi.org\/10.1093\/emboj\/18.16.4424.","journal-title":"EMBO J"},{"issue":"1","key":"1650_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4161\/cc.6.1.3665","volume":"6","author":"RS Jackson Ii","year":"2007","unstructured":"Jackson Ii RS, Cho YJ, Stein S, et al. CYFIP2, a direct p53 target, is leptomycin-B sensitive. Cell Cycl. 2007;6(1):95\u2013103. https:\/\/doi.org\/10.4161\/cc.6.1.3665.","journal-title":"Cell Cycl"},{"issue":"4","key":"1650_CR34","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3892\/ol.2017.5743","volume":"13","author":"S Jiao","year":"2017","unstructured":"Jiao S, Li N, Cai S, Guo H, Wen Y. Inhibition of CYFIP2 promotes gastric cancer cell proliferation and chemoresistance to 5-fluorouracil through activation of the Akt signaling pathway. Oncol Lett. 2017;13(4):2133\u201340. https:\/\/doi.org\/10.3892\/ol.2017.5743.","journal-title":"Oncol Lett"},{"issue":"3","key":"1650_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2008.12.002","volume":"136","author":"T Kawase","year":"2009","unstructured":"Kawase T, Ohki R, Shibata T, Tsutsumi S, Kamimura N, Inazawa J, Ohta T, Ichikawa H, Aburatani H, Tashiro F, Taya Y. PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell. 2009;136(3):535\u201350. https:\/\/doi.org\/10.1016\/j.cell.2008.12.002.","journal-title":"Cell"},{"issue":"11","key":"1650_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1457598","volume":"7","author":"S Jabeen","year":"2018","unstructured":"Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, L\u00fcders T, von der Lippe GH, Troyanskaya O, Kyte JA, B\u00f8rresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V. Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab. Oncoimmunology. 2018;7(11): e1457598. https:\/\/doi.org\/10.1080\/2162402X.2018.1457598.","journal-title":"Oncoimmunology"},{"issue":"10","key":"1650_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N, Melief CJM, Kastenm\u00fcller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635\u201347. https:\/\/doi.org\/10.1038\/s41577-018-0044-0.","journal-title":"Nat Rev Immunol"},{"key":"1650_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","volume":"222","author":"R Kennedy","year":"2008","unstructured":"Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev. 2008;222:129\u201344. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00616.x.","journal-title":"Immunol Rev"},{"issue":"18","key":"1650_CR39","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","volume":"12","author":"N Hiraoka","year":"2006","unstructured":"Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423\u2013\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0369.","journal-title":"Clin Cancer Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01650-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01650-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01650-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T13:11:41Z","timestamp":1736169101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01650-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01650-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"847"}}